INCA036873 for Cancer

Recruiting at 21 trial locations

Overseen By Incyte Corporation Call Center (ex-US)

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Incyte Corporation

Must not be taking: Immunosuppressants, Antivirals

Disqualifiers: CNS disease, Other malignancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

280 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called INCA036873, an experimental therapy, to determine its safety and tolerability in people with advanced cancers, specifically certain solid tumors and blood cancers. The study will examine how the drug works at different doses. Suitable candidates include those with cancers like kidney cancer or specific types of lymphoma that have not responded well to other treatments. Participants must have documented disease progression and specific cancer types confirmed by a doctor. The trial excludes individuals with untreated brain cancer or those who have recently undergone certain cancer treatments. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that INCA036873 is likely to be safe for humans?

Research has shown that INCA036873 is being tested for safety in people with advanced solid tumors and blood cancers. As this is the first phase of testing, limited safety information is available. During this phase, researchers focus on determining the right dose and monitoring for any side effects. This process helps ensure the treatment's safety before advancing to further studies.

Participants might experience side effects common to many cancer treatments, such as tiredness or nausea, but researchers closely monitor these effects. If this phase demonstrates that INCA036873 is well-tolerated, it could lead to larger studies to further assess its safety and effectiveness. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Researchers are excited about INCA036873 because it offers a new approach to cancer treatment by potentially targeting cancer cells more precisely than existing therapies. Unlike current standard treatments like chemotherapy and immunotherapy that broadly attack cancer cells, INCA036873 may work by honing in on specific molecular targets within the cancer cells, minimizing damage to healthy cells. This targeted approach not only promises to improve effectiveness but may also reduce side effects, making cancer treatment more tolerable for patients.

What evidence suggests that INCA036873 might be an effective treatment for cancer?

Research is testing INCA036873 to determine its effectiveness in treating advanced solid tumors and blood cancers. Although limited information exists on its efficacy in humans, the treatment aims to block specific pathways in cancer cells, potentially slowing or stopping their growth. Early studies have shown it might achieve this effect. Further research is underway to better understand its impact and confirm these initial findings. ^{1 3 5 6 7}

Who Is on the Research Team?

Incyte Study Monitor

Principal Investigator

Incyte Corporation

Are You a Good Fit for This Trial?

This trial is for adults over 18 with certain advanced cancers, including high-grade B-cell lymphoma, peripheral and cutaneous T-cell lymphomas, diffuse large B-cell lymphoma, and clear cell renal carcinoma. Participants must have had previous treatments specific to their cancer type and be in good physical condition (ECOG status of 0 or 1).

Inclusion Criteria

I am 18 years old or older.

I have had at least one treatment for kidney cancer that included immunotherapy and targeted therapy.

I am fully active or can carry out light work.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

INCA036873 is administered at the protocol defined dose to determine the maximum tolerated dose

Up to 28 days

Multiple visits for dose escalation and monitoring

Dose Expansion

INCA036873 is administered at the protocol defined dose to further evaluate safety and efficacy

Up to approximately 2 years

Regular visits for treatment and monitoring

Pharmacodynamic Cohort

INCA036873 is administered to assess pharmacodynamic effects

Up to approximately 2 years

Regular visits for pharmacodynamic assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to approximately 2 years and 90 days

What Are the Treatments Tested in This Trial?

Interventions

• INCA036873

Trial Overview

The study is testing the safety and how well people tolerate INCA036873—a potential new treatment for various advanced solid tumors and blood cancers.

How Is the Trial Designed?

Group I: Part 1c Pharmacodynamic Cohort Experimental Treatment 1 Intervention

INCA036873 will be administered at the protocol defined dose.

Group II: Part 1b Dose Expansion Experimental Treatment 1 Intervention

INCA036873 will be administered at the protocol defined dose.

Group III: Part 1a Dose Escalation Experimental Treatment 1 Intervention

INCA036873 will be administered at the protocol defined dose.

Who Is Running the Clinical Trial?

Incyte Corporation

Lead Sponsor

Trials

408

Recruited

66,800+

Steven Stein

Incyte Corporation

Chief Medical Officer since 2015

MD from University of Witwatersrand

Hervé Hoppenot

Incyte Corporation

Chief Executive Officer since 2014

MBA from ESSEC Business School

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT07195916

A Study to Evaluate INCA036873 in Participants With ...

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies. Official Title.

2.

incyteclinicaltrials.com

incyteclinicaltrials.com/studies/nct07195916

Advanced/Metastatic, GVHD

Clinical Study Purpose. A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

3.

incytemi.com

incytemi.com/node/731

INCA036873

An Open-Label, Multicenter Study of INCA036873 in Patients with Advanced Solid Tumors and Hematologic Malignancies. 1. NCT07195916 ...

4.

clinicaltrials.ucsd.edu

clinicaltrials.ucsd.edu/solid-tumor

UCSD Solid Tumor Clinical Trials for 2026 — San Diego

The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid ...

5.

clinicaltrials.ucbraid.org

clinicaltrials.ucbraid.org/kidney-cancer

Kidney Cancer clinical trials at University of California Health

This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging ...

6.

centerwatch.com

centerwatch.com/clinical-trials/listings/NCT07195916/a-study-to-evaluate-inca036873-in-participants-with-advanced-solid-tumors-and-hematological-malignancies

A Study to Evaluate INCA036873 in Participants With ...

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

7.

oncologypipeline.com

oncologypipeline.com/apexonco/grit-enters-vivo-car-t-race

Grit enters the in vivo Car-T race | ApexOnco

Incyte, meanwhile, is going into the clinic with a more traditional CD70-targeting T-cell engager, INCA036873 – but the phase 1 trial, in solid ...